Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
12 drugs in development
By Therapeutic Area
top 6
R&D Momentum
70/100
Pipeline Velocity
32/100
Trial Completion Rate
83/100
Pipeline Concentration
33/100
Pipeline Freshness
40/100
Strategic Signals
Activity
Last 14 days
Clinical Study of PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy in the Treatment of pMMR/MSS Locally Advanced Rectal Cancer
Development and Validation of Multimodal Deep Learning Model for Autonomous Diagnosis, Generative Reporting, and Specialist Referral in Ophthalmic Diseases: An International Multicenter Cohort Study
Institute of Sciences in Emergency Medicine - International Big Data Centre in Emergency Medicine
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)